CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

NewLimit snags $435M after seeing age reversal in human liver cells

Positive
AI Analysis

Summary

NewLimit raised $435M in funding and announced plans to accelerate clinical trials based on preclinical data showing its epigenetic reprogramming technology reversed aging in human liver cells.

Clinical Trial Data

Importance:6/10
Sentiment:
0.85
fundingepigenetic reprogrammingpreclinical dataliver cellsage reversal

Read the original article

Published by BioSpace on June 3, 2026 1:32 PM

Read Original